Sorry, you need to enable JavaScript to visit this website.


Terminated Clinical Trials

Study Identifier Study Name Disorders / CDG Type(s) Therapeutic approach Eligibility Study Type Industry / Institution(s) Region Location Contact Persons Direct Link
NCT02511041 Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation PGM3-CDG Drugs: N-Acetylglucosamine (GlcNAc) / Uridine
Administration: Oral
PGM3-CDG patients older than 2 years with immunologic abnormalities and altered glycosylation detected using clinical tests evaluating N- and O-linked glycan by mass spectroscopy Interventional Phase 1 National Institutes of Health Clinical Center

United States

Jonathan J Lyons, M.D.

Page modified at Monday, April 19, 2021 - 21:42